Evaluation of outcome and prognostic factors in patients of glioblastoma multiforme: A single institution experience

Journal of Neurosciences in Rural Practice

Volumn 4, Issue 5 SUPPL, 2013, Pages

  Kumar, Narendra ^a   Kumar, Pankaj ^a   Angurana, Shabab ^a   Khosla, Divya ^a   Mukherjee, Kanchan ^a   Aggarwal, Rupali ^a   Kumar, Ritesh ^a   Bera, Anjan ^a   Sharma, Suresh ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Glioblastoma multiforme; prognostic factors; radiotherapy; survival; temozolomide

Indexed keywords

COBALT; LOMUSTINE; TEMOZOLOMIDE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRAIN BIOPSY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COBALT TELETHERAPY; CRANIOTOMY; DECOMPRESSION SURGERY; DETERIORATION; DISEASE COURSE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INTRACRANIAL HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PARIETAL LOBE; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SEIZURE; SENSORIMOTOR NEUROPATHY; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR LOCALIZATION; VOMITING;

EID: 84884298102     PISSN: 09763147     EISSN: 09763155     Source Type: Journal    
DOI: 10.4103/0976-3147.116455     Document Type: Article

References (36)

1. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection and survival. J Neurosurg 2001;95:190-8.
2. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma Trials. J Natl Cancer Inst 1993;85:704-10.
3. Lutterbach J, Sauerbrei W, Guttenberger R. Multivariate analysis of Prognostic factors in patients with glioblastoma. Strahlenther Onkol 2003;179:8-15.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
5. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
6. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990,8:1277-80.
7. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group. Cancer 1981;47:649-52.
8. Laperriere N, Zuraw L, Cairncross G. The cancer care ontario practice guidelines initiative neuro-oncology disease site group. Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review. Radiother Oncol 2002;64:259-73.
9. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
10. Medical research council brain tumor working Party. Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: A medical research council trial. J Clin Oncol 2001;19:509-18.
11. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the glioma outcomes project. J Neurosurg 2003;99:467-73.
12. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333-43.
13. Bleehen NM, Stenning SP. A medical research council trial of two radiotherapy doses in the treatment of 3 and 4 astrocytoma. The medical research council brain tumor working party. Br J Cancer 1991;64:769-74.
14. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study. Cancer 1983;52:997-1007.
15. Nakagawa K, Aoki Y, Fujimaki T, Tago M, Terahara A, Karasawa K, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998;40:1141-9.
16. Chan JL, Lee SW, Frass BA. Survival and failure patterns of high grade glioma after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20:1635-42.
17. Kleinberg L, Slick T, Enger C, Grossman S, Brem H, Wharam MD Jr. Short course radiotherapy is an appropriate option for most malignant glioma patients. Int J Radiat Oncol Biol Phys 1997;38:31-6.
18. Lang O, Liebermeister E, Liesegang J, Sautter-Bihl ML. Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment. Strahlenther Onkol 1998;174:629-32.
19. Phillips C, Guiney M, Smith J, Hughes P, Narayan K, Quong G. A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiother Oncol 2003;68:23-6.
20. Manon R, Hui S, Chinnaiyan P, Suh J, Chang E, Timmerman R, et al. The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme. Technol Cancer Res Treat 2004;3:303-7.
21. Gundersen S, Lote K, Hannisdal E. Prognostic factors for glioblastoma multiforme-development of a prognostic index. Acta Oncol 1996;35:123-7.
22. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008;9:29-38.
23. Stenning SP, Freedman LS, Bleehen NM. Prognostic factors for high-grade malignant glioma: Development of a prognostic index. A report of the medical research council brain tumour working party. J Neurooncol 1990;9:47-55.
24. Hulshof MC, Schimmel EC, Andries Bosch D, Gonzalez Gonzalez D. Hypofractionation in glioblastoma multiforme. Radiother Oncol 2000;54:143-8.
25. Terasaki M, Eto T, Nakashima S, Okada Y, Ogo E, Sugita Y, et al. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. J Neurooncol 2011;102:247-53.
26. Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: A review of ten-year single institutional experience. J Neurooncol 2012;107:395-405.
27. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239-41.
28. Jeremic B, Grujicic D, Antunovic V, Djuric L, Stonjanovic M, Shibamoto Y. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol 1994;21:177-85.
29. Tait MJ, Petrik V, Loosemore A, Bell BA, Papadopoulos MC. Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: Analysis of 625 cases. Br J Neurosurg 2007;21:496-500.
30. Gehan EA, Walker MD. Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr 1977;46:189-95.
31. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62:753-64.
32. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115:3-8.
33. Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer 2012;118:5595-600.
34. Jalali R, Basu A, Gupta T, Munshi A, Menon H, Sarin R, Goel A. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: Single institution experience. Br J Neurosurg 2007;21:583-7.
35. Demirci U, Buyukberber S, Coskun U, Akmansu M, Yaman E, Baykara M, et al. Long term experience in high grade glial tumors with temozolomide. J Buon 2012;17:357-62.
36. Kocher M, Frommolt P, Borberg SK, Ruhi U, Steingraber M, Niewald M, et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 2008;184:572-9.